| Literature DB >> 33552861 |
Mi Mi Wan1, Huan Chen1, Zhong Da Wang2, Zhi Yong Liu1, Yue Qi Yu1, Lin Li2, Zhuo Yue Miao1, Xing Wen Wang1, Qi Wang1, Chun Mao1, Jian Shen1, Jia Wei2.
Abstract
Poor permeation of therapeutic agents and multidrug resistance (MDR) in solid tumors are the two major challenges that lead to the failure of the current chemotherapy methods. Herein, a zero-waste doxorubicin-loaded heparin/folic acid/l-arginine (HFLA-DOX) nanomotor with motion ability and sustained release of nitric oxide (NO) to achieve deep drug penetration and effective reversal of MDR in cancer chemotherapy is designed. The targeted recognition, penetration of blood vessels, intercellular penetration, special intracellular distribution (escaping from lysosomes and accumulating in Golgi and nucleus), 3D multicellular tumor spheroids (3D MTSs) penetration, degradation of tumor extracellular matrix (ECM), and reversal of MDR based on the synergistic effects of the motion ability and sustained NO release performance of the NO-driven nanomotors are investigated in detail. Correspondingly, a new chemotherapy mode called recognition-penetration-reversal-elimination is proposed, whose effectiveness is verified by in vitro cellular experiments and in vivo animal tumor model, which can not only provide effective solutions to these challenges encountered in cancer chemotherapy, but also apply to other therapy methods for the special deep-tissue penetration ability of a therapeutic agent.Entities:
Keywords: cancer therapy; deep‐penetration; degradation of tumor extracellular matrix; multidrug resistance; nanomotors; nitric oxide
Year: 2020 PMID: 33552861 PMCID: PMC7856908 DOI: 10.1002/advs.202002525
Source DB: PubMed Journal: Adv Sci (Weinh) ISSN: 2198-3844 Impact factor: 16.806